SSTR5 Modulators for Hyperinsulinemic Hypoglycemia
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current somatostatin receptor modulators, such as peptide analogs, are expensive, require frequent injections, and can cause injection site reactions, limiting their effectiveness in treating conditions like hyperinsulinemic hypoglycemia and acromegaly.
Innovation Solution
Development of small molecule non-peptidyl compounds that selectively modulate the somatostatin receptor subtype 5 (SSTR5), inhibiting insulin secretion and promoting glucose release, thereby treating hyperinsulinemic hypoglycemia and other conditions with reduced side effects and improved administration.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If peptide analogs (octreotide, lanreotide, pasireotide) are used as depot injections, then somatostatin receptor modulation efficacy is achieved, but treatment cost increases and administration convenience decreases
Solution Approach 1:
The patent changes the chemical nature parameter from peptide-based to small molecule non-peptidyl compounds, which fundamentally alters the pharmacokinetic properties and enables oral administration while maintaining SSTR5 selectivity and therapeutic efficacy
Solution Approach 2:
The patent replaces the mechanical injection system with an oral administration system, eliminating the need for frequent doctor's office visits and painful injections while achieving the same therapeutic goal through bioavailable small molecule compounds
2Reliability
If peptide analogs are administered via frequent injections, then hormone levels are normalized, but injection site reactions occur and patient burden increases
Solution Approach 1:
The patent replaces the injection administration route with oral administration, completely eliminating injection site reactions and associated patient discomfort while maintaining effective SSTR5 modulation for hormone level control
Solution Approach 2:
The patent transitions from expensive peptide analogs requiring repeated injections to orally available small molecule compounds with favorable pharmacokinetic profiles, reducing both direct treatment costs and indirect costs associated with frequent medical visits
3Ease of operation
If small molecule non-peptidyl compounds are developed for oral administration, then administration convenience improves and side effects are reduced, but selective SSTR5 modulation must be maintained
Solution Approach 1:
The patent applies local quality by designing small molecule compounds with specific structural features that confer selective affinity for SSTR5 over other somatostatin receptor subtypes, ensuring targeted modulation at the molecular level while enabling oral administration
Data Source
AI summary
Described herein are compounds that are somatostatin modulators, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds in the treatment of conditions, diseases, or disorders that would benefit from modulation of somatostatin activity.